Arrowstreet Capital
AMRI

Arrowstreet Capital’s Albany Molecular Research Inc AMRI Stock Holding History

Arrowstreet Capital’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,300
Closed -$343K – 1694
2015
Q4 		$343K Buy
+17,300
New +$329K ﹤0.01% 1219
2014
Q1 		– Sell
-54,513
Closed -$549K – 1459
2013
Q4 		$549K Buy
+54,513
New +$659K ﹤0.01% 952

Other funds holding AMRI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arrowstreet Capital's AMRI Position: Q1 2016 in Review

Arrowstreet Capital sold out of Albany Molecular Research Inc (AMRI) in Q1 2016, closing a stake of 17,300 shares — an estimated $343K sold.

Arrowstreet Capital first reported a position in AMRI in Q4 2013 and held it in 2 quarters. The position peaked at $549K in Q4 2013. 141 funds tracked by Wall St. Rank hold AMRI as of Q1 2016.

  • Arrowstreet Capital reported no remaining Albany Molecular Research Inc position as of Q1 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 17,300 Albany Molecular Research Inc shares in Q1 2016, an estimated $343K.
  • Arrowstreet Capital first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 2 quarters.
  • Arrowstreet Capital's Albany Molecular Research Inc position peaked at $549K in Q4 2013.
  • 141 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2016.

Based on Arrowstreet Capital's 13F filing for Q1 2016, filed 16 May 2016.